Vidit Bhandarkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vidit Bhandarkar has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Stefani Spranger
Koch Institute for Integrative Cancer Research, Massachusetts Institute for Technology, Cambridge, MA, USA
4 shared publications - Teresa Dinter
Koch Institute at MIT, Cambridge, MA 02139, USA
2 shared publications - Aerin Yang
Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA
1 shared publication - Amanda Robinson Kirane
Division of General Surgery, Department of Surgery, Section of Surgical Oncology, Stanford University School of Medicine, Stanford, CA, USA
1 shared publication - Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
1 shared publication - Anusha Kalbasi
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA
1 shared publication
Latest Publications
- Open Access
- 14 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6799) , eadx9954
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered “Trikines” to compel cis formation of three-chain cytokine receptor complexes at the cell surface that induce bespoke STAT transcriptional signaling programs. Trikines coactivated phosphorylation of STAT5 (pSTAT5) and pSTAT3 signatures distinct from natural cytokines by assembling trimeric combinations of interleukin-2 (IL-2), IL-10, and IL-21 receptors. In preclinical models, an IL-2–based Trikine restrained terminal differentiation of T cells, promoted stemness, and enhanced durability of tumor control without observable toxicity. An IL-10–based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in preclinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.
- 14 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6799) , eadx9954
Open AccessRewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Cytokines dimerize two receptor chains to activate Janus kinases and signal transducer and activator of transcription (STAT) transcription factors that regulate immune cells, but they have therapeutic liabilities. We engineered “Trikines” to compel cis formation of three-chain cytokine receptor complexes at the cell surface that induce bespoke STAT transcriptional signaling programs. Trikines coactivated phosphorylation of STAT5 (pSTAT5) and pSTAT3 signatures distinct from natural cytokines by assembling trimeric combinations of interleukin-2 (IL-2), IL-10, and IL-21 receptors. In preclinical models, an IL-2–based Trikine restrained terminal differentiation of T cells, promoted stemness, and enhanced durability of tumor control without observable toxicity. An IL-10–based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in preclinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.
- Open Access
Lymph node resident memory T cells retain effector capabilities by evading lung resident memory dysfunction
Resident memory T cells (T RM ) mediate localized immunity in barrier tissues while central memory T cells (T CM ) recirculate through lymphoid organs to surveil for reinfection. Although T RM are classically associated with peripheral non-lymphoid tissues, they have also been identified within lymph nodes (LN RM ) where the mechanisms guiding their formation and functional differences remain poorly understood. Here we used longitudinal antibody labeling to track the migratory history of memory T cells after influenza infection and demonstrate that CD69 + CD103 + T cells are resident in the lymph node. LN RM accumulate evenly throughout the lung-draining lymph node and are present within all analyzed LN compartments including, the sub capsular sinus, T cell zone and germinal centers. Epigenetic and transcriptional profiling reveal that LN RM are uniquely poised for cytotoxicity whereas T RM in the lung (Lung RM ) resemble exhausted cells with elevated expression of inhibitory receptors and increased chromatin accessibility at the Pdcd1 locus. Regulatory network analysis of transcription factors, combined with target gene expression and chromatin accessibility, identified key regulons differentiating T CM , LN RM and Lung RM states. Upon antigen re-encounter, LN RM are more proliferative, cytotoxic, and produce more IFNγ compared to Lung RM . Notably, we find that LN RM represent the most prevalent subset of memory T cells in human thoracic lymph nodes. These findings highlight functional heterogeneity in T RM and establish LN RM as a distinct and durable memory T cell population bridging features of circulating and tissue-resident cells.
Open AccessLymph node resident memory T cells retain effector capabilities by evading lung resident memory dysfunction
Resident memory T cells (T RM ) mediate localized immunity in barrier tissues while central memory T cells (T CM ) recirculate through lymphoid organs to surveil for reinfection. Although T RM are classically associated with peripheral non-lymphoid tissues, they have also been identified within lymph nodes (LN RM ) where the mechanisms guiding their formation and functional differences remain poorly understood. Here we used longitudinal antibody labeling to track the migratory history of memory T cells after influenza infection and demonstrate that CD69 + CD103 + T cells are resident in the lymph node. LN RM accumulate evenly throughout the lung-draining lymph node and are present within all analyzed LN compartments including, the sub capsular sinus, T cell zone and germinal centers. Epigenetic and transcriptional profiling reveal that LN RM are uniquely poised for cytotoxicity whereas T RM in the lung (Lung RM ) resemble exhausted cells with elevated expression of inhibitory receptors and increased chromatin accessibility at the Pdcd1 locus. Regulatory network analysis of transcription factors, combined with target gene expression and chromatin accessibility, identified key regulons differentiating T CM , LN RM and Lung RM states. Upon antigen re-encounter, LN RM are more proliferative, cytotoxic, and produce more IFNγ compared to Lung RM . Notably, we find that LN RM represent the most prevalent subset of memory T cells in human thoracic lymph nodes. These findings highlight functional heterogeneity in T RM and establish LN RM as a distinct and durable memory T cell population bridging features of circulating and tissue-resident cells.
- Top Cited Papers
- 17 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (103) , eadf4726
Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Immune responses against cancer are dominated by T cell exhaustion and dysfunction. Recent advances have underscored the critical role of early priming interactions in establishing T cell fates. In this review, we explore the importance of dendritic cell (DC) signals in specifying CD8 + T cell fates in cancer, drawing on insights from acute and chronic viral infection models. We highlight the role of DCs in lymph nodes and tumors in maintaining stem-like CD8 + T cells, which are critical for durable antitumor immune responses. Understanding how CD8 + T cell fates are determined will enable the rational design of immunotherapies, particularly therapeutic cancer vaccines, that can modulate DC–T cell interactions to generate beneficial CD8 + T cell fates.
- 17 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (103) , eadf4726
Top Cited PapersArchitects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Immune responses against cancer are dominated by T cell exhaustion and dysfunction. Recent advances have underscored the critical role of early priming interactions in establishing T cell fates. In this review, we explore the importance of dendritic cell (DC) signals in specifying CD8 + T cell fates in cancer, drawing on insights from acute and chronic viral infection models. We highlight the role of DCs in lymph nodes and tumors in maintaining stem-like CD8 + T cells, which are critical for durable antitumor immune responses. Understanding how CD8 + T cell fates are determined will enable the rational design of immunotherapies, particularly therapeutic cancer vaccines, that can modulate DC–T cell interactions to generate beneficial CD8 + T cell fates.
- 13 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (99) , eadi3487
Expansion of tumor-reactive CD8 + T cell clonotypes occurs in the spleen in response to immune checkpoint blockade
Immune checkpoint blockade (ICB) enhances T cell responses against cancer, leading to long-term survival in a fraction of patients. CD8 + T cell differentiation in response to chronic antigen stimulation is highly complex, and it remains unclear precisely which T cell differentiation states at which anatomic sites are critical for the response to ICB. We identified an intermediate-exhausted population in the white pulp of the spleen that underwent substantial expansion in response to ICB and gave rise to tumor-infiltrating clonotypes. Increased systemic antigen redirected differentiation of this population toward a more circulatory exhausted KLR state, whereas a lack of cross-presented tumor antigen reduced its differentiation in the spleen. An analogous population of exhausted KLR CD8 + T cells in human blood samples exhibited diminished tumor-trafficking ability. Collectively, our data demonstrate the critical role of antigen density within the spleen for the differentiation and expansion of T cell clonotypes in response to ICB.
- 13 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (99) , eadi3487
Expansion of tumor-reactive CD8 + T cell clonotypes occurs in the spleen in response to immune checkpoint blockade
Immune checkpoint blockade (ICB) enhances T cell responses against cancer, leading to long-term survival in a fraction of patients. CD8 + T cell differentiation in response to chronic antigen stimulation is highly complex, and it remains unclear precisely which T cell differentiation states at which anatomic sites are critical for the response to ICB. We identified an intermediate-exhausted population in the white pulp of the spleen that underwent substantial expansion in response to ICB and gave rise to tumor-infiltrating clonotypes. Increased systemic antigen redirected differentiation of this population toward a more circulatory exhausted KLR state, whereas a lack of cross-presented tumor antigen reduced its differentiation in the spleen. An analogous population of exhausted KLR CD8 + T cells in human blood samples exhibited diminished tumor-trafficking ability. Collectively, our data demonstrate the critical role of antigen density within the spleen for the differentiation and expansion of T cell clonotypes in response to ICB.